Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292210 | 0.88 | CYP1A2 (0.56) | SMPD1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL17261410 | 0.84 | SMPD1 (0.61) | SMPD1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL29375753 | 0.84 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL1029034 | 0.84 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL13216464 | 0.83 | HSP90AA1 (0.77) | HPGDCYP1A2HSP90AA1HSP90AB1BLM | |
| SCHEMBL8843713 | 0.83 | SMN1; SMN2 (0.90) | SMPD1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL8406613 | 0.82 | HPGD (0.56) | HPGDNPC1RAB9ASMN1; SMN2HSP90AA1 | |
| SCHEMBL4270566 | 0.82 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6HPGD | |
| Hydrochloric Acid SCHEMBL6586504 | 0.82 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL9236564 | 0.82 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097142-B1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | ZAMBON GROUP S.P.A | 2004-03-04 | — | — | US | disclosed |
| EP-1042300-B1 | PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-6498160-B2 | FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-12-24 | — | — | US | disclosed |
| US-6492360-B1 | Phthalazine derivatives phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-12-10 | — | — | US | disclosed |
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-05-16 | — | — | US | disclosed |
| US-6340684-B1 | TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-01-22 | — | — | US | disclosed |
| US-6329370-B1 | CARDIOVASCULAR DISORDERS AND TUMOR NECROSIS FACTOR (HEREINAFTER TNF.SUB..ALPHA.), A CYTOKINE WITH PRO-INFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2001-12-11 | — | — | US | disclosed |
| EP-1098886-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-16 | — | — | EP | disclosed |
| EP-1097142-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-09 | — | — | EP | disclosed |
| EP-1042300-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000005218-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
| WO-2000005219-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999032456-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SMPD1 36/4885HDAC1 45/4885HDAC8 79/4885 |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | PDE5A, PDE3B, PDE3A | SMPD1 456/4885HDAC1 105/4885HDAC8 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.